Close Menu

Reproductive Health

News on noninvasive prenatal testing, carrier screening, and preimplantation genetic screening.

During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.

Atrin will use Predictive's GenDB databases and women's health biobank to study germline mutations in DNA damage and response inhibitor pathways. 

A Chinese study involving NIPS data from almost two million pregnant women found that a new bioinformatic approach improves the detection of cancer.

Using BGI's sequencing technology, the firms plan to commercialize Natera's Signatera test in China and to develop reproductive health tests in "select markets."